What’s new

• Q1 FY27 revenue on track to exceed ₹150 cr, one of the strongest quarters ever.
• Full-year FY27 guidance raised by at least 10% to ₹660+ cr from ₹600 cr.
• Long-term supply agreement with PFSCM in Netherlands commenced.

Why it matters

A 10%+ guidance upgrade for a mid-cap signals sustained demand visibility across global markets. The PFSCM deal adds recurring institutional revenue, while favorable USD-INR realization should support margins. This could trigger upward revisions in earnings forecasts and a potential re-rating.

What we’re watching

• Q1 FY27 actual revenue and margin print due later.
• Order book conversion and pipeline strength in B2B healthcare.
• Any further guidance updates given current momentum.

The full read

Cupid just told the market that its first quarter of FY27 is shaping up to be one of the strongest in the company's history, with revenue exceeding ₹150 crore. That performance has prompted management to lift its full-year revenue guidance by at least 10% to ₹660+ crore. Hardly surprising given the visibility. The trigger: a string of international B2B healthcare wins, including a new long-term supply agreement with PFSCM in the Netherlands, plus continued momentum in male and female condom segments. For a ₹24,554 crore market cap company with trailing revenue growth of 112%, this guidance upgrade locks in a higher base. The open question is whether margins can hold as scale expands — the company says yes, citing USD-INR realisations and pricing trends. If Q1 delivers on its promise, the next set of analyst models will need a material reset.

Primary source: BSE · NSE